Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
How Diddy made himself the 'victim' in apology video where he does not mention ex
People visit 2024 Artist Project in Canada
'Liusanjie of New Generation' Sings for New Era
Water conservancy repairs were organized to ensure irrigation in Yangzhou
Defending champion South Carolina to open season in Las Vegas against Michigan
Developed countries must face up to their responsibilities to address climate change
Hangzhou Asian Games opening new, inspiring chapter for China's sports undertaking
U.S. leads world in economic coercion
Children are evacuated from school 'during an exam' after threat made via email
Girl, five, dies in horror crash with a lorry while riding her bike outside the school gates
Patrick Reed withdraws from US Open qualifying and ends streak of playing the majors
Xinhua Commentary: Xi's Meeting with Ma Injects Positive Energy to Relations Across Taiwan Strait